A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 14, 2016

Study Completion Date

October 2, 2017

Conditions
Hodgkin Disease
Interventions
DRUG

Brentuximab Vedotin

Monoclonal antibody drug conjugate

Trial Locations (12)

Unknown

Queen Elizabeth Hospital, Birmingham

University Hospital of Wales, Cardiff

Beatson West of Scotland Cancer Center, Glasgow

St James University Hospital, Leeds

University Hospital, Leicester

Royal Liverpool Hospital, Liverpool

Guys Hospital, London

The Freeman Hospital, Newcastle

Norfolk and Norwich Hospital, Norwich

The Churchill Hospital, Oxford

Southampton General Hospital, Southampton

M20 4BX

The Christie Hospital, Manchester

Sponsors
All Listed Sponsors
collaborator

Leukaemia Lymphoma Research

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Birmingham

OTHER